Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway
Non-small cell lung cancer (NSCLC) is a prominent subtype of lung carcinoma that accounts for the majority of cancer-related deaths globally, and it is responsible for about 80% to 85% of lung cancers. Mitogen-Activated Protein Kinase (MAPK) signaling pathways are a vital aspect of NSCLC, and have a...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.741326/full |
| _version_ | 1819095498260217856 |
|---|---|
| author | Anisha S. Jain Ashwini Prasad Sushma Pradeep Chandan Dharmashekar Raghu Ram Achar Ekaterina Silina Victor Stupin Raghavendra G. Amachawadi Shashanka K. Prasad R Pruthvish Asad Syed Chandan Shivamallu Shiva Prasad Kollur |
| author_facet | Anisha S. Jain Ashwini Prasad Sushma Pradeep Chandan Dharmashekar Raghu Ram Achar Ekaterina Silina Victor Stupin Raghavendra G. Amachawadi Shashanka K. Prasad R Pruthvish Asad Syed Chandan Shivamallu Shiva Prasad Kollur |
| author_sort | Anisha S. Jain |
| collection | DOAJ |
| description | Non-small cell lung cancer (NSCLC) is a prominent subtype of lung carcinoma that accounts for the majority of cancer-related deaths globally, and it is responsible for about 80% to 85% of lung cancers. Mitogen-Activated Protein Kinase (MAPK) signaling pathways are a vital aspect of NSCLC, and have aided in the advancement of therapies for this carcinoma. Targeting the Ras/Raf/MEK/ERK pathway is a promising and alternative method in NSCLC treatment, which is highlighted in this review. The introduction of targeted medicines has revolutionized the treatment of patients with this carcinoma. When combined with current systems biology-driven stratagems, repurposing non-cancer drugs into new therapeutic niches presents a cost-effective and efficient technique with enhancing outcomes for discovering novel pharmacological activity. This article highlights the successful cutting-edge techniques while focusing on NSCLC targeted therapies. The ultimate challenge will be integrating these repurposed drugs into the therapeutic regimen of patients affected with NSCLC to potentially increase lung cancer cure rates. |
| first_indexed | 2024-12-21T23:44:15Z |
| format | Article |
| id | doaj.art-cef8880cbeeb4573b0800957ce2527d6 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-21T23:44:15Z |
| publishDate | 2021-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-cef8880cbeeb4573b0800957ce2527d62022-12-21T18:46:09ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-10-011110.3389/fonc.2021.741326741326Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling PathwayAnisha S. Jain0Ashwini Prasad1Sushma Pradeep2Chandan Dharmashekar3Raghu Ram Achar4Ekaterina Silina5Victor Stupin6Raghavendra G. Amachawadi7Shashanka K. Prasad8R Pruthvish9Asad Syed10Chandan Shivamallu11Shiva Prasad Kollur12Department of Microbiology, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, IndiaDepartment of Microbiology, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, IndiaDepartment of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, IndiaDepartment of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, IndiaDivision of Biochemistry, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, IndiaDepartment of Human Pathology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, RussiaDepartment of Hospital Surgery, N.I. Pirogov Russian National Research Medical University (RNRMU), Moscow, RussiaDepartment of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS, United StatesDepartment of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, IndiaDepartment of Biotechnology, Acharya Institute of Technology, Bengaluru, IndiaDepartment of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi ArabiaDepartment of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, IndiaDepartment of Sciences, Amrita School of Arts and Sciences, Amrita Vishwa Vidyapeetham, Mysuru, IndiaNon-small cell lung cancer (NSCLC) is a prominent subtype of lung carcinoma that accounts for the majority of cancer-related deaths globally, and it is responsible for about 80% to 85% of lung cancers. Mitogen-Activated Protein Kinase (MAPK) signaling pathways are a vital aspect of NSCLC, and have aided in the advancement of therapies for this carcinoma. Targeting the Ras/Raf/MEK/ERK pathway is a promising and alternative method in NSCLC treatment, which is highlighted in this review. The introduction of targeted medicines has revolutionized the treatment of patients with this carcinoma. When combined with current systems biology-driven stratagems, repurposing non-cancer drugs into new therapeutic niches presents a cost-effective and efficient technique with enhancing outcomes for discovering novel pharmacological activity. This article highlights the successful cutting-edge techniques while focusing on NSCLC targeted therapies. The ultimate challenge will be integrating these repurposed drugs into the therapeutic regimen of patients affected with NSCLC to potentially increase lung cancer cure rates.https://www.frontiersin.org/articles/10.3389/fonc.2021.741326/fullnon-small cell lung cancerdrug repurposing/repositioningMAPKtargeted therapyinhibitors |
| spellingShingle | Anisha S. Jain Ashwini Prasad Sushma Pradeep Chandan Dharmashekar Raghu Ram Achar Ekaterina Silina Victor Stupin Raghavendra G. Amachawadi Shashanka K. Prasad R Pruthvish Asad Syed Chandan Shivamallu Shiva Prasad Kollur Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway Frontiers in Oncology non-small cell lung cancer drug repurposing/repositioning MAPK targeted therapy inhibitors |
| title | Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway |
| title_full | Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway |
| title_fullStr | Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway |
| title_full_unstemmed | Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway |
| title_short | Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway |
| title_sort | everything old is new again drug repurposing approach for non small cell lung cancer targeting mapk signaling pathway |
| topic | non-small cell lung cancer drug repurposing/repositioning MAPK targeted therapy inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.741326/full |
| work_keys_str_mv | AT anishasjain everythingoldisnewagaindrugrepurposingapproachfornonsmallcelllungcancertargetingmapksignalingpathway AT ashwiniprasad everythingoldisnewagaindrugrepurposingapproachfornonsmallcelllungcancertargetingmapksignalingpathway AT sushmapradeep everythingoldisnewagaindrugrepurposingapproachfornonsmallcelllungcancertargetingmapksignalingpathway AT chandandharmashekar everythingoldisnewagaindrugrepurposingapproachfornonsmallcelllungcancertargetingmapksignalingpathway AT raghuramachar everythingoldisnewagaindrugrepurposingapproachfornonsmallcelllungcancertargetingmapksignalingpathway AT ekaterinasilina everythingoldisnewagaindrugrepurposingapproachfornonsmallcelllungcancertargetingmapksignalingpathway AT victorstupin everythingoldisnewagaindrugrepurposingapproachfornonsmallcelllungcancertargetingmapksignalingpathway AT raghavendragamachawadi everythingoldisnewagaindrugrepurposingapproachfornonsmallcelllungcancertargetingmapksignalingpathway AT shashankakprasad everythingoldisnewagaindrugrepurposingapproachfornonsmallcelllungcancertargetingmapksignalingpathway AT rpruthvish everythingoldisnewagaindrugrepurposingapproachfornonsmallcelllungcancertargetingmapksignalingpathway AT asadsyed everythingoldisnewagaindrugrepurposingapproachfornonsmallcelllungcancertargetingmapksignalingpathway AT chandanshivamallu everythingoldisnewagaindrugrepurposingapproachfornonsmallcelllungcancertargetingmapksignalingpathway AT shivaprasadkollur everythingoldisnewagaindrugrepurposingapproachfornonsmallcelllungcancertargetingmapksignalingpathway |